Skip to content
HowShorted

Tvardi Therapeutics, Inc. short interest in 2018

In 2018, Tvardi Therapeutics, Inc.'s disclosed short interest ran from 19.89% of shares outstanding on 12 Jan 2018 to 14.08% on 31 Dec 2018, a change of -5.81 percentage points. The year's high was 23.41% on 30 Apr 2018 and its low 13.21% on 14 Sep 2018, averaging 18.46% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.50 days on 30 Nov 2018. Full history: Tvardi Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Tvardi Therapeutics, Inc. in 2018

2018 in figures

Start of year
19.89% (12 Jan 2018)
End of year
14.08% (31 Dec 2018)
Change
-5.81 pp
High
23.41% (30 Apr 2018)
Low
13.21% (14 Sep 2018)
Average
18.46%
Highest days to cover
18.50 (30 Nov 2018)
SEC filings marked
9

Every report in 2018

Tvardi Therapeutics, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201819.89%6.22
31 Jan 201820.39%3.97
15 Feb 201821.74%6.00
28 Feb 201820.62%11.91
15 Mar 201822.10%11.2510-K filed, results (8-K)
29 Mar 201823.17%6.93
13 Apr 201822.97%12.97
30 Apr 201823.41%17.79
15 May 201822.17%13.3010-Q filed, results (8-K)
31 May 201820.91%2.38
15 Jun 201821.28%7.49
29 Jun 201820.89%3.35
13 Jul 201819.44%8.00
31 Jul 201817.14%5.25results (8-K)
15 Aug 201814.35%7.8410-Q filed, results (8-K)
31 Aug 201813.36%9.15
14 Sep 201813.21%8.53
28 Sep 201814.06%5.61
15 Oct 201815.90%8.97
31 Oct 201814.88%10.86
15 Nov 201815.04%11.7010-Q filed, results (8-K)
30 Nov 201816.23%18.50
14 Dec 201815.81%8.75
31 Dec 201814.08%7.17

See also: Tvardi Therapeutics, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.